XstalBio tackles challenging biologic formulations (required dosing too frequent, controlled release of API required, competitors hold blocking formulation patents, better adjuvant needed for target antigens, etc… ).
XstalBio tackles challenging biologic formulations (required dosing too frequent, controlled release of API required, competitors hold blocking formulation patents, better adjuvant needed for target antigens, etc… ).
CEVEC aims to become the leading independent player for human cell line based clinical materials. CEVEC offers the human amniocyte based protein expression platform CAP for the transient and stable production of biopharmaceuticals.